D2M Biotherapeutics Announces First Patient Dosed in A Phase 1 Study Evaluating

Posted on by

DM919, a Novel MICA/B Antibody for Treating Patients with Advanced Solid Tumors NATICK, Mass., April 18, 2024 /PRNewswire/ — D2M Biotherapeutics, Inc. (D2M), a clinical stage biotech company focused on developing innovative therapies in treating Immunological-Inflammatory diseases and…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.